The estimated Net Worth of Alice Lin Tsing Yu is at least $197 Tysiąc dollars as of 10 April 2017. Alice Yu owns over 20,000 units of Opko Health Inc stock worth over $156,000 and over the last 15 years he sold OPK stock worth over $0. In addition, he makes $41,000 as Independent Director at Opko Health Inc.
Alice has made over 6 trades of the Opko Health Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of OPK stock worth $94,400 on 10 April 2017.
The largest trade he's ever made was exercising 20,000 units of Opko Health Inc stock on 10 April 2017 worth over $94,400. On average, Alice trades about 5,455 units every 59 days since 2009. As of 10 April 2017 he still owns at least 100,000 units of Opko Health Inc stock.
You can see the complete history of Alice Yu stock trades at the bottom of the page.
Dr. Alice Lin-Tsing Yu M.D., Ph.D. serves as Independent Director of the Company. From mid-2013 to 2018, Dr. Yu served as Distinguished Chair Professor and Co-Director of The Institute of Stem Cell & Translational Cancer Research at Chang Gung Memorial Hospital. From 2003 to May, 2013, Dr. Yu served as Distinguished Research Fellow and Associate Director at the Genomics Research Center, Academia Sinica, in Taiwan. She has been a Professor of Pediatrics for the University of California in San Diego since 1994. Previously, she was the Chief of Pediatric Hematology Oncology at the University of California in San Diego. Dr. Yu has also served in several government-appointed positions and is a member of numerous scientific committees and associations. Dr. Yu is an accomplished physician, professor, and researcher who brings a unique perspective to our Board on a variety of healthcare related issues. As a pioneer in immunotherapy of neuroblastoma, Dr. Yu was instrumental in developing a monoclonal anti-GD2 (Dinutuximab) from IND through early phase studies and phase III trials, and facilitating its FDA approval on March 10, 2015. The insight and experience gained from her distinguished record of achievement at several highly respected academic medical institutions, as well as her experience as a practicing physician, continues to be valuable to our efforts to develop and commercialize our pipeline of diagnostic and therapeutic products.
As the Independent Director of Opko Health Inc, the total compensation of Alice Yu at Opko Health Inc is $41,000. There are 13 executives at Opko Health Inc getting paid more, with Phillip Frost having the highest compensation of $1,405,200.
Alice Yu is 76, he's been the Independent Director of Opko Health Inc since 2009. There are 5 older and 16 younger executives at Opko Health Inc. The oldest executive at Opko Health Inc is John Paganelli, 85, who is the Independent Director.
Alice's mailing address filed with the SEC is OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI, FL, 33137.
Over the last 17 years, insiders at Opko Health Inc have traded over $862,245 worth of Opko Health Inc stock and bought 128,867,460 units worth $425,265,065 . The most active insiders traders include Phillip Md Et Al Frost Neva..., Phillip Md Et Al Frost Gamm... oraz Phillip Md Et Al Frost Gamm.... On average, Opko Health Inc executives and independent directors trade stock every 4 days with the average trade being worth of $142,696. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 23 May 2024, trading 100,000 units of OPK stock currently worth $127,000.
opko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig
Opko Health Inc executives and other stock owners filed with the SEC include: